Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma
Crossref DOI link: https://doi.org/10.1007/s00277-016-2901-x
Published Online: 2017-01-10
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jimenez-Zepeda, Victor H
Duggan, Peter
Neri, Paola
Tay, Jason
Bahlis, Nizar J
License valid from 2017-01-10